• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病性心肌病:相关病理生理机制

The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms.

作者信息

Salvatore Teresa, Pafundi Pia Clara, Galiero Raffaele, Albanese Gaetana, Di Martino Anna, Caturano Alfredo, Vetrano Erica, Rinaldi Luca, Sasso Ferdinando Carlo

机构信息

Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy.

出版信息

Front Med (Lausanne). 2021 Jun 30;8:695792. doi: 10.3389/fmed.2021.695792. eCollection 2021.

DOI:10.3389/fmed.2021.695792
PMID:34277669
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8279779/
Abstract

Individuals with diabetes mellitus (DM) disclose a higher incidence and a poorer prognosis of heart failure (HF) than non-diabetic people, even in the absence of other HF risk factors. The adverse impact of diabetes on HF likely reflects an underlying "diabetic cardiomyopathy" (DM-CMP), which may by exacerbated by left ventricular hypertrophy and coronary artery disease (CAD). The pathogenesis of DM-CMP has been a hot topic of research since its first description and is still under active investigation, as a complex interplay among multiple mechanisms may play a role at systemic, myocardial, and cellular/molecular levels. Among these, metabolic abnormalities such as lipotoxicity and glucotoxicity, mitochondrial damage and dysfunction, oxidative stress, abnormal calcium signaling, inflammation, epigenetic factors, and others. These disturbances predispose the diabetic heart to extracellular remodeling and hypertrophy, thus leading to left ventricular diastolic and systolic dysfunction. This Review aims to outline the major pathophysiological changes and the underlying mechanisms leading to myocardial remodeling and cardiac functional derangement in DM-CMP.

摘要

糖尿病患者发生心力衰竭(HF)的发生率高于非糖尿病患者,且预后更差,即使不存在其他HF危险因素也是如此。糖尿病对HF的不利影响可能反映了潜在的“糖尿病性心肌病”(DM-CMP),左心室肥厚和冠状动脉疾病(CAD)可能会加剧这种情况。自首次描述以来,DM-CMP的发病机制一直是研究的热点,目前仍在积极研究中,因为多种机制之间的复杂相互作用可能在全身、心肌和细胞/分子水平上发挥作用。其中包括代谢异常,如脂毒性和糖毒性、线粒体损伤和功能障碍、氧化应激、异常钙信号传导、炎症、表观遗传因素等。这些紊乱使糖尿病心脏易于发生细胞外重塑和肥大,从而导致左心室舒张和收缩功能障碍。本综述旨在概述导致DM-CMP中心肌重塑和心脏功能紊乱的主要病理生理变化及其潜在机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/8279779/5e36650fd10c/fmed-08-695792-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/8279779/4c029d6682e0/fmed-08-695792-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/8279779/5e36650fd10c/fmed-08-695792-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/8279779/4c029d6682e0/fmed-08-695792-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f40b/8279779/5e36650fd10c/fmed-08-695792-g0002.jpg

相似文献

1
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms.糖尿病性心肌病:相关病理生理机制
Front Med (Lausanne). 2021 Jun 30;8:695792. doi: 10.3389/fmed.2021.695792. eCollection 2021.
2
Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.糖尿病性心肌病:导致这一临床实体的机制更新。
Circ Res. 2018 Feb 16;122(4):624-638. doi: 10.1161/CIRCRESAHA.117.311586.
3
Role of AMP-activated protein kinase on cardio-metabolic abnormalities in the development of diabetic cardiomyopathy: A molecular landscape.AMP 激活的蛋白激酶在糖尿病心肌病发展中心血管代谢异常中的作用:分子全景。
Eur J Pharmacol. 2020 Dec 5;888:173376. doi: 10.1016/j.ejphar.2020.173376. Epub 2020 Aug 15.
4
Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy.糖尿病心肌病中的分子功能障碍和表型紊乱。
Int J Mol Sci. 2019 Jul 2;20(13):3264. doi: 10.3390/ijms20133264.
5
Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants.糖尿病性心肌病中心脏功能障碍的机制:分子异常与表型变异
Heart Fail Rev. 2023 May;28(3):597-606. doi: 10.1007/s10741-021-10200-y. Epub 2022 Jan 10.
6
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues.全身衰老引发心力衰竭:分子机制与治疗途径
ESC Heart Fail. 2025 Apr;12(2):1059-1080. doi: 10.1002/ehf2.14947. Epub 2024 Jul 22.
7
Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy.糖尿病心肌病的发病机制、临床特征及治疗。
Adv Exp Med Biol. 2018;1067:197-217. doi: 10.1007/5584_2017_105.
8
Mechanisms and Therapeutic Prospects of Diabetic Cardiomyopathy Through the Inflammatory Response.糖尿病心肌病通过炎症反应的机制及治疗前景
Front Physiol. 2021 Jun 21;12:694864. doi: 10.3389/fphys.2021.694864. eCollection 2021.
9
Heart Failure in Type 2 Diabetes Mellitus.2 型糖尿病中的心力衰竭。
Circ Res. 2019 Jan 4;124(1):121-141. doi: 10.1161/CIRCRESAHA.118.311371.
10
Diabetes Mellitus and Heart Failure.糖尿病与心力衰竭
J Clin Med. 2021 Aug 19;10(16):3682. doi: 10.3390/jcm10163682.

引用本文的文献

1
Mechanisms and therapeutics of insulin signaling transduction genes in diabetic cardiomyopathy: a comprehensive updated review.糖尿病性心肌病中胰岛素信号转导基因的机制与治疗:全面更新综述
Front Endocrinol (Lausanne). 2025 Jul 17;16:1589695. doi: 10.3389/fendo.2025.1589695. eCollection 2025.
2
Sea buckthorn flavonoids and their derivatives: potential natural compounds for the treatment of diabetic cardiomyopathy.沙棘黄酮及其衍生物:治疗糖尿病性心肌病的潜在天然化合物。
Front Pharmacol. 2025 Jul 17;16:1599756. doi: 10.3389/fphar.2025.1599756. eCollection 2025.
3
Insights for lncH19, miR-9, and miR-146a expression levels and their cross-talk with pro-inflammatory cytokines, copeptin, and neopterin profile in type 1 diabetic cardiomyopathy.

本文引用的文献

1
Pathophysiology, Clinical Characteristics of Diabetic Cardiomyopathy: Therapeutic Potential of Natural Polyphenols.糖尿病性心肌病的病理生理学、临床特征:天然多酚的治疗潜力
Front Nutr. 2020 Dec 3;7:564352. doi: 10.3389/fnut.2020.564352. eCollection 2020.
2
The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.二肽基肽酶-4抑制剂、胰高血糖素样肽-1受体激动剂及钠-葡萄糖协同转运蛋白2/1抑制剂对有或无心力衰竭病史的糖尿病患者心力衰竭结局的影响:来自心血管结局试验及药物机制的见解
Front Endocrinol (Lausanne). 2020 Dec 1;11:599355. doi: 10.3389/fendo.2020.599355. eCollection 2020.
3
1型糖尿病性心肌病中长链非编码RNA H19、微小RNA-9和微小RNA-146a的表达水平及其与促炎细胞因子、 copeptin和新蝶呤谱的相互作用研究
Mol Biol Rep. 2025 Jun 13;52(1):592. doi: 10.1007/s11033-025-10672-3.
4
Effects of 12-week combined interval running and resistance training on cardiac structure and performance in patients with type 1 diabetes.12周联合间歇跑步和阻力训练对1型糖尿病患者心脏结构和功能的影响。
Ther Adv Endocrinol Metab. 2025 Mar 28;16:20420188251325148. doi: 10.1177/20420188251325148. eCollection 2025.
5
A New Perspective on the Role of Alterations in Mitochondrial Proteins Involved in ATP Synthesis and Mobilization in Cardiomyopathies.关于参与心肌病中ATP合成与转运的线粒体蛋白改变作用的新视角
Int J Mol Sci. 2025 Mar 19;26(6):2768. doi: 10.3390/ijms26062768.
6
Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight.糖尿病中的线粒体功能障碍:揭示一个普遍存在的疏忽。
Pathophysiology. 2025 Feb 13;32(1):9. doi: 10.3390/pathophysiology32010009.
7
Mechanisms of inflammatory microenvironment formation in cardiometabolic diseases: molecular and cellular perspectives.心脏代谢疾病中炎症微环境形成的机制:分子与细胞视角
Front Cardiovasc Med. 2025 Jan 14;11:1529903. doi: 10.3389/fcvm.2024.1529903. eCollection 2024.
8
Sodium-dependent glucose transporter 2 inhibitors improve heart function in patients with type 2 diabetes and heart failure.钠-葡萄糖协同转运蛋白2抑制剂可改善2型糖尿病合并心力衰竭患者的心脏功能。
World J Cardiol. 2025 Jan 26;17(1):100886. doi: 10.4330/wjc.v17.i1.100886.
9
Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy-Challenges and Prospectives.糖尿病性心肌病药物治疗的批判性评价——挑战与展望
Pharmaceuticals (Basel). 2025 Jan 20;18(1):134. doi: 10.3390/ph18010134.
10
Oxidative Stress and Cardiovascular Complications in Type 2 Diabetes: From Pathophysiology to Lifestyle Modifications.2型糖尿病中的氧化应激与心血管并发症:从病理生理学到生活方式改变
Antioxidants (Basel). 2025 Jan 9;14(1):72. doi: 10.3390/antiox14010072.
Myocardial glucotoxicity: Mechanisms and potential therapeutic targets.
心肌糖毒性:机制与潜在治疗靶点。
Arch Cardiovasc Dis. 2020 Nov;113(11):736-748. doi: 10.1016/j.acvd.2020.06.006. Epub 2020 Nov 12.
4
The influence of diabetes and prediabetes on left heart remodeling: A population-based study.糖尿病和糖尿病前期对左心重构的影响:一项基于人群的研究。
J Diabetes Complications. 2021 Feb;35(2):107771. doi: 10.1016/j.jdiacomp.2020.107771. Epub 2020 Oct 24.
5
Increased O-GlcNAcylation induces myocardial hypertrophy.糖基化修饰增加可诱导心肌肥大。
In Vitro Cell Dev Biol Anim. 2020 Oct;56(9):735-743. doi: 10.1007/s11626-020-00503-z. Epub 2020 Sep 29.
6
A novel oral glucagon-like peptide 1 receptor agonist protects against diabetic cardiomyopathy via alleviating cardiac lipotoxicity induced mitochondria dysfunction.一种新型口服胰高血糖素样肽-1受体激动剂通过减轻心脏脂毒性诱导的线粒体功能障碍来预防糖尿病性心肌病。
Biochem Pharmacol. 2020 Dec;182:114209. doi: 10.1016/j.bcp.2020.114209. Epub 2020 Aug 27.
7
DNA methyltransferase-1 inactivation of androgen receptor axis triggers homocysteine induced cardiac fibroblast autophagy in diabetic cardiac fibrosis.DNA 甲基转移酶 1 失活雄激素受体轴触发同型半胱氨酸诱导的糖尿病心脏纤维化中心脏成纤维细胞自噬。
Arch Biochem Biophys. 2020 Oct 15;692:108521. doi: 10.1016/j.abb.2020.108521. Epub 2020 Aug 12.
8
Endothelial Dysfunction: A Contributor to Adverse Cardiovascular Remodeling and Heart Failure Development in Type 2 Diabetes beyond Accelerated Atherogenesis.内皮功能障碍:2型糖尿病中不良心血管重塑和心力衰竭发展的一个促成因素,超越加速动脉粥样硬化。
J Clin Med. 2020 Jul 3;9(7):2090. doi: 10.3390/jcm9072090.
9
Targeting Cardiac Stem Cell Senescence to Treat Cardiac Aging and Disease.靶向心脏干细胞衰老治疗心脏衰老和疾病。
Cells. 2020 Jun 26;9(6):1558. doi: 10.3390/cells9061558.
10
Mibefradil Alleviates High-Glucose-induced Cardiac Hypertrophy by Inhibiting PI3K/Akt/mTOR-mediated Autophagy.米贝地尔通过抑制 PI3K/Akt/mTOR 介导的自噬减轻高糖诱导的心肌肥厚。
J Cardiovasc Pharmacol. 2020 Aug;76(2):246-254. doi: 10.1097/FJC.0000000000000844.